Dynamics of Kidney Function in Patients with Chronic Kidney Disease and Atrial Fibrillation Who Receive Dabigatran

Dynamics of Kidney Function in Patients with Chronic Kidney Disease and Atrial Fibrillation Who Receive Dabigatran

Atrial fibrillation (AF) is the most frequent type of supraventricular arrhythmias. The anticoagulant therapy should be prescribed to prevent thromboembolic events. According to randomized clinical trials, anticoagulants do not always prove their high efficiency in the real clinical practice. It is...

Full description

Bibliographic Details
Main Authors:	N. A. Novikova, Z. K. Salpagarova, M. I. Chashkina, A. A. Bykova, Z. A. Alimova, А. S. Yadykina, D. F. Mesitskaya, N. A. Babakova, D. A. Andreev
Format:	Article
Language:	English
Published:	Stolichnaya Izdatelskaya Kompaniya 2021-05-01
Series:	Racionalʹnaâ Farmakoterapiâ v Kardiologii
Subjects:	atrial fibrillation chronic kidney disease anticoagulants warfarin bleeding
Online Access:	https://www.rpcardio.com/jour/article/view/2426

Similar Items

Warfarin vs. apixaban in nonvalvular atrial fibrillation, and analysis by concomitant antiarrhythmic medication use: A national retrospective study
by: Matthew A. Wanat, et al.
Published: (2019-10-01)

Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation
by: N. A. Novikova, et al.
Published: (2016-11-01)

Assessment of Antithrombotic Therapy in Patients with Atrial Fibrillation for 2015-2017 According to the Registry of the Clinic of the Scientific Research Institute of Medical Problems of the North of Krasnoyarsk City
by: A. A. Tuchkov, et al.
Published: (2019-03-01)

ANTICOAGULATION CONTROL AMONG PATIENTS WITH ATRIAL FIBRILLATION
by: Amer Rauf, et al.
Published: (2020-12-01)

ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION: NEW DATA AND NEW HORIZONS
by: M. Yu. Gilyarov, et al.
Published: (2016-01-01)

Algorithm for the Choice of Anticoagulant for Patients with Atrial Fibrillation
by: Yu. P. Skirdenko, et al.
Published: (2020-05-01)

Safety of Using Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Chronic Kidney Disease
by: V. I. Petrov, et al.
Published: (2019-09-01)

Resumption of anticoagulant therapy after major bleeding and recurrence of hemorrhagic complications in patients with atrial fibrillation with a high risk of stroke and thromboembolism (based on the results of 20 years of observation)
by: A. I. Mironova (Staroverova), et al.
Published: (2020-10-01)

Anticoagulation for Atrial Fibrillation in End-stage Kidney Disease
by: Gavin Lee, et al.
Published: (2015-10-01)

Contribution of anticoagulant therapy adherence to the risk of complications of atrial fibrillation
by: Yu. P. Skirdenko, et al.
Published: (2019-03-01)

Warfarin therapy in atrial fibrillation: assessment of patient knowledge of risks and benefits
by: P. Fitzgerald, et al.
Published: (2020-05-01)

Factors driving the use of warfarin and non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
by: Mu-Mei Hu, et al.
Published: (2017-04-01)

Warfarin doses for anticoagulation therapy in elderly patients with chronic atrial fibrillation
by: Antonio de Padua Mansur, et al.
Published: (2012-01-01)

Newer Anticoagulants for Non-Valvular Atrial Fibrillation
by: Joseph M. Harburger, et al.
Published: (2012-05-01)

Outcomes and direct treatment costs with novel oral anticoagulants compared to clinic-monitored warfarin for stroke prevention in atrial fibrillation
by: Hulvershorn, Sarah Elizabeth
Published: (2014)

Characteristics and 2‐year outcomes of dabigatran treatment in patients with heart failure and atrial fibrillation: GLORIA‐AF
by: Sergio J. Dubner, et al.
Published: (2020-10-01)

Dabigatran in the prevention of stroke in nonvalvular atrial fibrillation: Complex clinical situations and real clinical practice
by: O N Tkacheva, et al.
Published: (2014-04-01)

Control Of Anticoagulation Therapy in Atrial Fibrillation (COAT-AF Study) in Real Clinical Practice
by: A. A. Zarudsky, et al.
Published: (2020-03-01)

Features of Modern Anticoagulant Therapy in Patients with Nonvalvular Atrial Fibrillation and Chronic Kidney Disease
by: I. S. Daabul, et al.
Published: (2016-11-01)

POSSIBILITY OF NOVEL ORAL ANTICOAGULANTS USAGE DURING ABLATION IN ATRIAL FIBRILLATION
by: B. A. Tatarsky, et al.
Published: (2014-12-01)

The use of warfarin in veterans with atrial fibrillation
by: Rosenbeck Karen, et al.
Published: (2004-10-01)

Evaluation of oral anticoagulants in atrial fibrillation patients over 80 years of age with nonsevere frailty
by: Masaya Shinohara, et al.
Published: (2019-12-01)

Concerns Regarding the Use of Dabigatran for Stroke Prevention in Atrial Fibrillation
by: Josef Finsterer, et al.
Published: (2012-02-01)

Traditional warfarin (Coumadin) therapy usage experience on nonvalvular atrial fibrillation before non-Vitamin K antagonists (new oral anticoagulants) era from a center in Turkey
by: Emre Ozdemir, et al.
Published: (2020-01-01)

Glycemic status and risks of thromboembolism and major bleeding in patients with atrial fibrillation
by: Yi-Hsin Chan, et al.
Published: (2020-03-01)

Report of periprocedural oral anticoagulants in catheter ablation for atrial fibrillation: The Japanese Catheter Ablation Registry of Atrial Fibrillation (J-CARAF)
by: Yuji Murakawa, MD, et al.
Published: (2017-06-01)

Dabigatran Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation: An Evidence Based Case Report
by: Alvin Nursalim, et al.
Published: (2013-06-01)

COMPARISON OF SCHEMES OF PERIOPERATIONAL ANTICOAGULATION IN ATRIAL FIBRILLATION PATIENTS DEMANDING FOR SURGERY
by: L. N. Uddin, et al.
Published: (2018-06-01)

Optimal INR level in patients with atrial fibrillation with EHRA type 2 valvular heart disease receiving warfarin
by: Sirote Luengsupabul, et al.
Published: (2020-06-01)

Atrial fibrillation and stroke in the perspective of new oral anticoagulants
by: Demet Funda Baş, et al.
Published: (2013-02-01)

Clinical characteristics and antithrombotic status in 621 very elderly hospitalized patients with atrial fibrillation
by: Wen Liu, et al.
Published: (2018-01-01)

Warfarin therapy in patients with coronary heart disease and atrial fibrillation: drug interactions and genetic sensitivity to warfarin
by: O. A. Panibratiuk, et al.
Published: (2020-06-01)

Quality of anticoagulation control among patients with atrial fibrillation: An experience of a tertiary care center in Saudi Arabia
by: Sarah M. Alyousif, et al.
Published: (2016-10-01)

Antithrombotic Therapy in Elderly Patients with Atrial Fibrillation: The State of the Problem in the Real Clinical Practice of a Family Medicine Doctor
by: Bazira Kanat кyzy, et al.
Published: (2021-06-01)

First report of dabigatran reversal in iatrogenic pericardial tamponade during catheter ablation of atrial fibrillation
by: Jared D. Miller, MD, et al.
Published: (2017-12-01)

PRACTICAL APPLICATION OF DABIGATRAN ETEXILATE FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION
by: E. D. Kosmacheva, et al.
Published: (2015-09-01)

Anticoagulation therapy in atrial fibrillation after intracranial hemorrhage
by: A. S. Gerasimenko, et al.
Published: (2021-05-01)

Comparison of benefit between dabigatran and warfarin among patients with atrial fibrillation: A systematic review
by: Amal K Sulieman
Published: (2016-01-01)

Possibility of using dabigatran in patients with atrial fibrillation and acute coronary syndrome and PCI
by: A. D. Erlich
Published: (2019-04-01)

Prevention of heart embolic complications in atrial fibrillation: Possibilities of using rivaroxaban
by: I S Iavelov
Published: (2013-12-01)